Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine ModelsLi Shen, Роберто Пили, Mona Celander et al.|Cancer Immunology Research|2014Cited by 90
Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies: Safety and proof of mechanism.Martijn P. Lolkema, Sarah P. Blagden, Elizabeth Ruth Plummer et al.|Journal of Clinical Oncology|2019Cited by 1